This cluster groups 2 independently calculated changes: Cash & equivalents decreased 36.8%; Operating cash flow decreased 56.5%.
2 evidence-backed components· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTAura Biosciences, Inc.'s latest supported as-filed period reports net income of -$45.6M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 36.8%; Operating cash flow decreased 56.5%.
2 evidence-backed componentsFree-cash-flow proxy changed -56.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
AURA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001946505-26-000009SEC ↗4Sep 1, 2026Period Sep 1, 20260002148785-26-000009SEC ↗4Sep 1, 2026Period Sep 1, 20260001997710-26-000004SEC ↗4Sep 1, 2026Period Sep 1, 20260002042910-26-000003SEC ↗4Sep 1, 2026Period Sep 1, 20260002148701-26-000008SEC ↗10-QAug 11, 2026Period Jun 30, 20260001193125-26-343429SEC ↗8-KAug 11, 2026Period Aug 11, 20260001193125-26-343408SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 1, 2026Filed Sep 1, 2026 | Kratz EricaChief Reg. & Quality Officer | Grant Or AwardDirect | 100,885 | $0 | $0 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | Kratz EricaChief Reg. & Quality Officer | Grant Or AwardDirect | 199,115 | $0 | $0 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | Person JulieChief People Officer | Grant Or AwardDirect | 107,611 | $0 | $0 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | Person JulieChief People Officer | Grant Or AwardDirect | 212,389 | $0 | $0 | Form 4 ↗ |
| Jul 7, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating cash flow changed -56.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current assets changed +78.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Total assets changed +70.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Working capital changed +83.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Shares outstanding changed +66.9% from the comparable as-filed period. The change ranks at the 88th percentile of 8 prior comparable changes.
Operating income changed -68.0% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-335157| Bender JeremyDirector |
| Grant Or AwardDirect |
| 30,000 |
| $0 |
| $0 |
| Form 4 ↗ |
| Jul 7, 2026Filed Jul 8, 2026 | Bender JeremyDirector | Grant Or AwardDirect | 60,000 | $0 | $0 | Form 4 ↗ |